Upload
topaz-galz
View
225
Download
0
Embed Size (px)
Citation preview
8/6/2019 Hypersensitivity MedChula
1/27
1
Principle of Immunology 3 2554
Hypersensitivity
..
Gell and Coombs Classification
4 , effector molecules
1. Type I hypersensitivity Immediate type (IgE-mediated) hypersensitivity2. Type II hypersensitivity Antibody-mediated cytotoxic hypersensitivity3. Type III hypersensitivity Immune complex-mediated hypersensitivity4. Type IV hypersensitivity Delayed-type hypersensitivity
Type I (Immediate type (IgE-mediated)) hypersensitivity
1
humoral immune response T helper 2 (Th2)
IgE IgE highaffinity Fc receptor mast cell basophil IgE mast cell basophil cross-links IgE sensitized mast cell basophil (Degranulation) (Mediators) 1
8/6/2019 Hypersensitivity MedChula
2/27
2
(allergen)(inhalants)
(ingestants) injectants
IgE(cytophilic antibody) FC recetor(FcRI, FcRII) mast cell basophil species homocytotropic antibody
FcRI IgE mast cell basophil
(mediators) processing antigen presenting cell T cell MHC class II Th2 cell B cell plasmacell IgE IgE Fc receptor IgE mast cell basophil sensitization specific IgE cross-linkage (bridging) IgE 2
GTP-dependent stimulatory G-protein (Gs)
adenylate cyclase adenosine triphosphate (ATP) cyclicadenosine monophosphate (cAMP) inactivate protein kinase A activate protein kinase A cAMP protein tyrosine kinase(PTK) phospholipase C phosphatidyl inositol 4,5-bisphosphate(PIP2) inositoltriphosphate(IP3) diacylglycerol(DAG) activate protein kinase A, inositoltriphosphate(IP3) diacylglycerol(DAG) calcium ion( Ca2+) sarcoplasmic reticulum (SER) cytosol DAG activated cytosol protein P DAG DAG-lipase monoacylglycerol(MAG) free fatty acid(FFA) activated cytosol protein P, MAG, FFA cAMP
8/6/2019 Hypersensitivity MedChula
3/27
3
methylation phospholipid calcium channel calcium (calcium influx)
Degranulation cAMP MAG, FFA cytosolprotein P (fusogens) (mediators) degranulation mast cell basophil IgE cross-bridging anaphylactoid reaction
o Anaphylatoxin C3a, C4a,C5a
o radio contrast media, morphine, aspirin,chymopapain
o Anti-idiotype antibody anti-isotype antibody intravenousimmunoglobulin
o Anti-Fc receptor antibodyo Ca2+ influx Ca2+ ionophore
8/6/2019 Hypersensitivity MedChula
4/27
4
mast cell degranulation
degranulation (mediators) 2
I. (primary or preformed mediators) mast cell basophil degranulation
1. Histamine
decarboxylation histidine histamine receptor 4 H1, H2,H3 H4 receptor 1 histamineH
1receptor,
[vascular permeability] mucous secretion globletcell histamine 1-2 10 histaminase histamine
H1 receptor antihistamine hydroxyzine,chlorpheniramine, diphenhydramine
histamineH2receptor, gastricparietal cell histamine H2 receptor mast cell basophil mast cell basophil negative feedback degranulation mast cell
basophilhistamineH2receptor H2-receptor antagonist ranitidine femotidine
H3 receptor H
1 H
2receptor H
4receptor
neutrophil, eosinophil, basophil, mast cell T helper cell histamine H3 H4 receptorcAMP
2. Eosinophilic chemotactic factor of anaphylaxis [ECF-A]
8/6/2019 Hypersensitivity MedChula
5/27
8/6/2019 Hypersensitivity MedChula
6/27
6
LTD4 LTE4 vascular permeability histamine 100
leukotriene prostaglandin
30-60 degranulation mast cell basophil neutrophil,macrophage, eosinophil leukotriene prostaglandin early late phase 1
leukotriene slow-reacting substance of anaphylaxis [SRS-A] histamine
2.2 Prostaglandins [PG] Thromboxanes metabolism arachidonic acid
leukotriene cyclo-oxygenase pathwayprostaglandin permeability prostaglandin prostaglandin D
2[PGD
2]
vasodilatation [wheal and flare]
thromboxane thromboxane A2 [TXA2] thromboxane B2[TXB2] leukotrienes, prostaglandins thromboxanes arachidonic acid pathway pathway pathway non-steroidal anti-inflammatory drugs [NSAIDs] aspirin, diclofenac ibuprofen
cyclo-oxygenase pathway leukotrieneslipooxygenasepathway bronchoconstriction
2.3 Platelets activating factor [PAF]
acetyl glyceryl ether phosphoryl choline [AGEPC] mast cell, basophil, neutrophil, monocyte macrophage vasoactiveamine platelet factor-4 [PL4], histamine, serotonin, thromboxane A2 [TXA2]
8/6/2019 Hypersensitivity MedChula
7/27
7
thromboxane B2 [TXB2] PAF histamine 100-1,000 eosinophil
PAF ketotifen
2.4 Kinins
decapeptide protease enzyme kininogens kallikreins kininsbradykinin , vascular permeability mucous gland
2.5 Cytokines
mastcell,basophileosinophil 1 IL-3,IL-4, IL-5, IL-6, IL-10, IL-13 TNF- neutrophil, eosinophil late phase response IL-4 IL-13 Th2 response IgE IL-
5 eosinophil TNF- shock systemic anaphylaxis
4-8 late phase reaction PAF, LTC, IL-4, IL-5, TNF-, ECF-A, NCF-A
anaphylactic shock allergic asthma anaphylactic shock2 anaphylactic shock allergic asthma
8/6/2019 Hypersensitivity MedChula
8/27
8
1
Primary mediators Actions
Histamine, heparin ,
Serotonin () ,
Eosinophil chemotactic factor (ECF-A) eosinophil
Neutrophil chemotactic factor (NCF-A) neutrophil
Proteases (tryptase, chymase) vascular basementmembrane ,
Secondary mediators Actions
Leukotrienes (slow reacting substance of
anaphylaxis, SRS-A),
Prostaglandins, Thromboxanes , ,
Platelet- activating factor ,
Kinin ,
Cytokines , adhesion molecule, IgE , systemicanaphylaxis
8/6/2019 Hypersensitivity MedChula
9/27
9
1 mediator
1. [bronchospasm]
2. vascular permeability shock intravascular fluid interstitial space
3. mucous secretion 4. late phase reaction5. histamine
1 [systemic anaphylaxis]
1. Anaphylaxis 1 15-30
, , anaphylactic shock epinephrine anaphylaxis , antiserum,
2. Allergic asthma mucus secretion [wheeze] inhalants , , ,
8/6/2019 Hypersensitivity MedChula
10/27
10
3. Allergic rhinitis 20%
anaphylaxis typeI hypersensitivity mediators 40-50% (aeroallergen)
4. Allergic conjunctivitisAllergic rhinitis 2
5. Urticaria AngioedemaUrticaria (wheal),
(flare) 1,3 ingestants ,, ,
Angioedema urticaria [dermis] [subcutis], [genitalia] [laryngeal edema]
angioedema bradykinins C1inhibitor deficiency, angiotensin-converting enzymeinhibitors [ACEIs] angiotensin II receptor blockers [ARBs]
6. Atopic dermatitis
8/6/2019 Hypersensitivity MedChula
11/27
11
eczema 1
atopic dermatitis 1 ingestion inhalation
7. Food allergy
ingestants , , anaphylaxis
Type II hypersensitivity Antibody-mediated cytotoxic hypersensitivity
2
basement membrane antibody-dependent cell mediated cytotoxicity(ADCC)
2
hapten , hapten hapten-carriercomplex immunogenicity B lymphocyte hemolytic anemia
IgG IgM
8/6/2019 Hypersensitivity MedChula
12/27
12
NK cell phagocytic cells neutrophil monocyte
, glomerular basement membrane,alveolar basement membrane basement membrane
IgG IgM 1. [agglutination]
phagocytic system reticuloendothelial system
2.
classical pathway membrane attack complex anaphylatoxin, opsonin chemotacticfactor
3. IgG C3b opsonin Fc receptor CR1 C3breceptor phagocyte phagocytosis opsonization
4. IgG Fc receptor NK-cell,neutrophil monocyte lytic enzyme phagocytosis antibody-dependent cell mediated cytotoxicity ADCC
ADCC MAC classical pathway
8/6/2019 Hypersensitivity MedChula
13/27
8/6/2019 Hypersensitivity MedChula
14/27
14
[Rh- blood group] Rh- antibody D antigen D antigen Rh+ Anti-D antibody anti-Rh antibody
Hemolytic disease of the newborn due to Rh incompatibility Rh- D antigen IgG anti-D antibody Rh+
a. Rh- D Rh+ mismatch
transfusion
b. Rh+
trophoblast trophoblast [fetomaternal transplacental bleeding] D anti-D antibody anti-Rhantibody IgM primary immune response
Rh+ IgG anti-D antibody[IgG2]D [extravascular hemolysis]
fetomaternal transplacental bleeding invasiveprocedures amniocentesis, chorionic villous sampling [CVS]
antiDantibody
o Anemia
8/6/2019 Hypersensitivity MedChula
15/27
15
o Jaundice indirect [unconjugated] hyperblirubinemia heme indirect
bilirubin
o Hepatosplenomegaly extravascularhemolysis
o Immune hydrops fetalis secondarytissue hypoxia [high-output heart failure]
, hydropsfetalis 50-98
o Maternal blood group
ABO Rh Rh- anti-Dantibody
o Paternal blood group Rh+
Rh+ Rh isoimmunization o Indirect Coombs test
Anti-D antibody
D Anti-D antibody D Anti-globulin antibody Coombs reagent reagent [agglutination]
anti-D antibody antibody titer Rh isoimmunization
8/6/2019 Hypersensitivity MedChula
16/27
16
antibody titer 1:8
o Ultrasonography Rh isoimmunization
, , hydrops fetalis amniocentesis umbical vein blood sampling
o Amniocentesis indirect bilirubin
Rh isoimmunization
Rh fetal amniocyte PCR technique o Umbilical vein blood sampling
[fetalhemoglobin] Rhisoimmunization indirect bilirubin
Rh isoimmunization Rhogam IgG Anti-D antibody Rh- Anti-Dantibody Rhogam IgG anti-D antibody D antigen Anti-D antibody Rhogam i. 28 72 2 ii. 72
fetomaternal bleeding amniocentesis, chorionic villous sampling, spontaneousabortion 8
Rhogam anti-D antibody Rh- 99% Rhogam anti-D antibody Rh-
8/6/2019 Hypersensitivity MedChula
17/27
17
D anti-D antibody
Rh incompatibility
3. Hyperacute graft rejection4. Immune thrombocytopenic purpura [ITP]5. Autoimmune diseases
2 Autoimmune hemolytic anemia [AIHA] Goodpastures syndrome
Type III hypersensitivity Immune complex-mediated hypersensitivity 3 (soluble antigen)
( Ag excess) (circulating immune complex) basement membrane
8/6/2019 Hypersensitivity MedChula
18/27
18
3 IgG IgMIgG IgM
(exogenous antigen) antivenin, , , trimethoprim-sulfamethoxazole, (endogenous antigen) nucleosome, immunoglobulin autoimmune disease
neutrophil, mast cell, platelets,
3:2 (immunecomplex) basement membrane glomerular basement membrane , synovialmembrane synovial joint, choroids plexus CNS (slight antibody excess) immune complex
Arthus reaction immune complex
1. C3a, C5a C5b67 chemotactic factor neutrophil lytic enzyme
2. C3a, C4a C5a anaphylatoxin degrabulation mast cell basophil histamine, leukotrienes vasodilatation vascular permeability
3. immune complex platelet-activating factor [PAF] mast cell vasoactive amine endothelial cell immunecomplex basement membrane endothelium
4. immune complex
8/6/2019 Hypersensitivity MedChula
19/27
19
immune complex complement
1. Serum sicknessSerum sickness
, , , (Hymenoptera sting) circulating immune complex
8/6/2019 Hypersensitivity MedChula
20/27
20
hapten Hapten-carrier complex immune complex serum sickness-like reaction serumsickness penicillins, radiocontrast media, cephalosporins cefaclor, sulfonamides,streptomycin, thiouracils, hydantoins, dextran, hydralazine, propranolol, metronidazole
serum sickness (glonerulonephritis) serum sickness 7-14 IgG IgM secondaryimmune response 2-4 accelerated serum sickness
atopy serum sickness IgE vasoactive amine immunecomplex skin test 1 serumsickness
2. Arthus reaction
immune complex immune complex 3 tetanus toxoid
8/6/2019 Hypersensitivity MedChula
21/27
21
6-8 24-48 tissue necrosis
arthus reaction bacterialspores, fungi fecal protein (pneumonitis, alveolitis)
3. Systemic lupus erythematosus (SLE)SLE prototype systemic autoimmune diseases autoantibodies immune complexes ) 3 immune complex
turbulence flow, , (butterfly rash), , , ,, ,
4. Rheumatoid arthritis
(chronic inflammatory synovitis)synovial 2, , , vasculitis, subcutaneous nodule vasculitis acute rheumaticfever rheumatoid arthritis
Fc IgG rheumatoid factor 19s IgM 7s IgM, IgG IgA rheumatoid factor rheumatoid arthritis 75-90% RFSLE, Sjgrens syndrome,Polyarteritis nodosa
5. Acute post-streptococcal glomerulonephritis [APSGN]
8/6/2019 Hypersensitivity MedChula
22/27
22
GroupA streptococcus nephritogenic strain 1-4
streptococcus [molecular mimicry] immune complex 3 streptococcus alternate pathway
microscopichematuria, proteinuria,
Type IV hypersensitivity Delayed-type hypersensitivity
4
sensitizedT lymphocyte T helper 1 cell cytotoxic T cell
4 graft,
intracellular pathogen , (contactant) , , nickels
T lymphocyte TH1 TC cell, macrophage
3 1. Sensitization
antigen-presenting cell class II MHC sensitizedTH1 cell 1-2
2. Elicitation
antigen-
presenting cell sensitized T cell 2
8/6/2019 Hypersensitivity MedChula
23/27
23
TH1 cell TH1 cytokine IFN- TNF-macrophage 24-72
TC cell cytotoxic Tcell specific antigenic determinant
4 1. ,
macrophage
2. specific target cell cytotoxic T cell 3.
4 activated macrophage epitheloid cell multinucleated giant cell fibroblast fibrosis
necrosis chronic granuloma
1. Allergic contact dermatitis
,
( 1000dalton) hapten allergen antigen presenting cell T lymphocyte regionallymph node T cell memory T cell memory T cell cytotoxic T cell Langerhans cell sensitized T cell 4
8/6/2019 Hypersensitivity MedChula
24/27
24
2. Intracellular infection , leprosy [],
o caseous granuloma
o Mycobacterium leprae
tuberculoid leprosy CMI ,
lepromatous leprosy CMI chronic granuloma
granulomatous inflammation
3. Acute allograft rejection4. Graft-versus-host disease (GVHD)
8/6/2019 Hypersensitivity MedChula
25/27
25
I IgE-mediated
(immediate)
hypersensitivity
2-30 Ag induces cross-linking of IgE bound to
mast cells with release
of vasoactive mediators
Systemic anaphylaxis,allergic
rhinitis , Asthma, Atopic
dermatitis
II Antibody-
mediated
cytotoxic
hypersensitivity
5-8 Ab directed againstcell-surface antigens
mediates cell
destruction via ADCC
or complement
Blood transfusion reactions,
Haemolytic disease of the
newborn, Autoimmune
Haemolytic anaemia
III Immune-
complex
mediated
hypersensitivity
2-8 Ag-Ab complexesdeposited at various
sites induces mast cell
degranulation via
FcgammaRIII, PMN
degranulation damages
tissue
Arthus reaction , serum sickness
acute post-streptococcal
glomerulonephritis
IV cell-mediated
(delay type)
hypersensitivity
24-72 Memory Th1 cellsrelease cytokines that
recruit and activate
macrophages, Tc cells
Contact dermatitis, Tubercular
lesions
8/6/2019 Hypersensitivity MedChula
26/27
26
1. , : . 1. :
, 2543: 192-207.
2. . Leprosy. : . 2 4. : , 2545: 60-9.
3. . Acute poststreptococcal glomerulonephritis. : , , , . 3. :, 2547: 183-94.
4. Abbas AK, Lichtman AH, Pober JS. Hypersensitivity disease. In: Abbas AK, LichtmanAH, Pober JS. Basic Immunology: Functions and disorders of the immune system. 2
nd
edition. Saunder Elsevier,2006:193-208.
5. Brady HR, Omeara YM, Brenner BM. Glomerular disease. In: Kasper DL, BraunwaldE, Fauci AS, HauserSL, Jameson JL. Harrisons Principle of Internal Medicine. 16thedition. New York: McGraw-Hill medical publishing division, 2005: 1680-1.
6. Chosidow OM, Stern RS, Wintroub BU. Cutaneous drug eruption. In: Kasper DL,Braunwald E, Fauci AS, HauserSL, Jameson JL. Harrisons Principle of InternalMedicine. 16
thedition. New York: McGraw-Hill medical publishing division, 2005: 318-
324.
7. Goldsby RA, Kindt TJ and Osborne BA. Hypersensitive reactions. In: Goldsby RA,Kindt TJ and Osborne BA. Immunology. 5
thedition. New York: W.H. Freeman and
company, 2003: 361-87.
8. Gomella TL. Blood abnormalities. In: Gomella TL. Neonatology. 5 th edition USA:McGraw-Hill companies,2004: 344-9.
9. Hedley AG, Laboratory assays for predicting the severity of haemolytic disease of thefetus and newborn. Transpl Immunol 2002; 10: 191.
10. Janeway CA, Travers P, Walport M, Schlomchik m. Allergy and Hypersensitivity. In:Janeway CA, Travers P, Walport M, Schlomchik m. Immunobiology. 6
thedition. New
York: Garland Publishing,2006: 517-50.
11. Nairn R, Helbert M. Hypersensitivity reactions. In: Nairn R, Helbert M. Immunology forMedical Students. Elsevier/Mosby,2006: 215-67.
8/6/2019 Hypersensitivity MedChula
27/27